Deal facts
- Buyer
- Aimei Health Technology Co., Ltd
- Target
- Hera Health Solutions Inc.
- Deal value
- Not disclosed
- Announced
- 17 November 2026
- Status
- Possible offer
- Sector
- Healthcare
- Country
- United States
- Consideration
- shares
Sources
Aimei Health Technology Co., Ltd (Nasdaq: AFJK), a Cayman Islands blank check company, entered into a non-binding letter of intent on November 14, 2026 for a business combination with Hera Health Solutions Inc. Under the letter of intent, Aimei would acquire 100% of Hera's outstanding equity and equity equivalents in exchange for shares of the combined public company. The terms were disclosed in a Form 8-K under Item 7.01 (Regulation FD Disclosure), signed by chief executive officer Junheng Xie on November 17, 2026. The filing gives no aggregate value or exchange ratio.
Hera is described in the filing as a pharmaceutical technology company headquartered in Memphis, Tennessee. It is developing drug delivery products built on a proprietary biodegradable nanofiber scaffold technology, an electrospinning manufacturing platform and AI-driven formulation capabilities. Its technology is meant to reformulate existing medicines into long-acting implants, patches and other formats with sustained release. Its Hercules AI technology targets formulation development across women's health, infectious diseases, pain management and metabolic disorders.
The letter of intent is non-binding except for certain provisions, including confidentiality and exclusivity. Aimei says it expects to announce further details when a definitive business combination agreement is executed, and it states there is no assurance that one will be signed or that the transaction will close.
The filing lists the remaining steps: negotiating and signing definitive agreements, completing due diligence, and obtaining the required regulatory and shareholder approvals. If a definitive agreement is signed, Aimei or a holding company formed for the transaction intends to file a Form F-4 or Form S-4 registration statement with the SEC containing a preliminary proxy statement/prospectus. A definitive proxy statement/prospectus would then be mailed to Aimei shareholders for a vote on the transaction.
Deal timeline
1 update- Possible offer
Aimei Health Technology Co., Ltd signs non-binding letter of intent to acquire Hera Health Solutions Inc.
Item 7.01. Regulation FD Disclosure. On November 14, 2026, Aimei Health Technology Co., Ltd (the “ Company ”) entered into a non-binding letter of intent (the “ LOI ”) for a business combination (the “ Proposed Transaction ”) with Hera Health Solutions Inc., a Tennessee biotechnology and medical device company (“ Hera ”). Under the terms of the LOI, the Company and Hera would become a combined ent
Source
For business owners
What would selling your own business involve?
Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.
Guides are free to read. Free tools require email access; indicative results are not professional advice.
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited
Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…
- Buyer
- Circle Health Holdings Limited
- Target
- CHC Healthcare Holdings Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Drugs Made In America Acquisition II Corp. to acquire Alpha AI Biotech Group
Drugs Made in America Acquisition II Corp., a Cayman Islands special purpose acquisition company listed on Nasdaq, disclosed in a Form 8-K signed November 18, 2026 that…
- Buyer
- Drugs Made In America Acquisition II Corp.
- Target
- Alpha AI Biotech Group
- Deal value
- USD 600,000,000
- Deal type
- strategic acquisition
Wolfram Resources Plc to acquire Ellipses Pharma Limited
Wolfram Resources Plc (LSE: WFR), a Main Market listed special purpose acquisition company, confirmed on 16 November 2026 that it was in active discussions about a poten…
- Buyer
- Wolfram Resources Plc
- Target
- Ellipses Pharma Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
MaxCyte, Inc. to acquire Akron BioProducts LLC
MaxCyte, Inc., the Nasdaq-listed cell-engineering company, has agreed to acquire Akron BioProducts LLC from affiliates of Arcline Investment Management. The Securities P…
- Buyer
- MaxCyte, Inc.
- Target
- Akron BioProducts LLC
- Deal value
- USD 151,800,000
- Deal type
- strategic acquisition
New Horizon Pharma B.V. to acquire Phatebo GmbH
ZeroStack Corp. disclosed in a Form 8-K, accepted by the SEC on 9 November 2026, that on 3 November 2026 it signed a Share Purchase and Transfer Agreement with New Horiz…
- Buyer
- New Horizon Pharma B.V.
- Target
- Phatebo GmbH
- Deal value
- EUR 2,150,000
- Deal type
- strategic acquisition
Buyer history
Aimei Health Technology Co., Ltd
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive